Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DA-EPOCH +/- Rituximab + Tafasitamab-cxix in Newly-Diagnosed Ph- B-ALL
NCT05453500Phase 2Active, not recruiting
- Sponsor
- University of Washington
- Start
- Mar 2023
- Primary completion
- Apr 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tafasitamab in acute lymphoblastic leukemia (ALL), sponsored by University of Washington. Started Mar 2023; status: active, not recruiting.
02
Drugs
tafasitamab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT05453500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05453500.